Prophylactic Bevacizumab May Mitigate Radiation Injury: An Experimental Study


Aslan A., KAYA Z. B., Bulduk E. B., Ocal O., Ucar M., Erpolat O. P., ...More

WORLD NEUROSURGERY, vol.116, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 116
  • Publication Date: 2018
  • Doi Number: 10.1016/j.wneu.2018.06.094
  • Journal Name: WORLD NEUROSURGERY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Hacettepe University Affiliated: Yes

Abstract

BACKGROUND: Stereotactic radiosurgery (SRS) is widely used to treat brain pathologies alone or in concert with other treatment modalities. However, there are some side effects, such as radiation injury characterized by edema and necrosis in peripheral tissues, that must be managed. A new treatment agent against this side effect is bevacizumab, which targets increased vascular endothelial growth factor (VEGF) as a prominent etiologic factor in radiation injury. In this study, we created a rat experimental model to describe the effects of both radiation and the anti-VEGF monoclonal antibody bevacizumab following high-dose SRS, and to compare the effects of prophylactic and delayed-onset bevacizumab treatment.